Hormone pill tested for prostate troubles – but trial halted early
NCT ID NCT00651807
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a hormone drug called etonogestrel (Org 3236) in 16 men with moderate to severe urinary symptoms from an enlarged prostate. The goal was to see if the drug could shrink the prostate, improve urine flow, and boost quality of life compared to a placebo. However, the study was terminated early, so the findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- etonogestrel (a hormone drug)
- What this could lead to
- If it works, this could point toward a new hormone-based treatment for enlarged prostate symptoms.
- What could go wrong
- This was a very small, early-phase trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BENIGN PROSTATIC HYPERPLASIA (BPH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Instituto Médico Especializado
Buenos Aires, Hidalgo, 1405, Argentina
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Steam and scans: a sharper way to shrink an enlarged prostate?
- New prostate surgery technique aims to shorten operation time
- Laser vs bipolar: which surgery best tames an oversized prostate?
- Banana flower extract tested to ward off prostate trouble
- New probe zaps away prostate troubles in landmark trial
- Waterjet surgery for BPH under the microscope: 3,000-Patient registry launches